Creating Value by Overcoming Treatment Barriers View previous quarters - Today Latest News View all press releases 11.03.26 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Read More 10.27.26 Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET Read More 10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More Events View all events Upcoming Events 11.04.26 8:00 AM EST Q3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call Past Events 11.04.26 8:00 AM EST Q3 2026 Aquestive Therapeutics, Inc. Earnings Conference Call 09.14.26 9:00 AM EDT H.C. Wainwright 28th Annual Global Investment Conference Presentations View all presentations Corporate Presentation – September 2026 Anaphylm Human Factors and Clinical Study Supplemental Materials 1.7 MB Anaphylm™ (dibutepinephrine) Sublingual Film Complete Response Letter Supplemental Material 1.1 MB
11.03.26 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Read More
10.27.26 Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET Read More
10.15.26 Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 Read More
